-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Post Menopausal Osteoporosis (Alvotech SA)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Denosumab Biosimilar in Post Menopausal Osteoporosis Drug Details: AVT-03 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Golimumab Biosimilar in Inflammation
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Golimumab Biosimilar in Inflammation Drug Details:Monoclonal antibody is under development for the treatment of inflammation, rheumatoid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Febuxostat + Inosine) in Mitochondrial Diseases
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.(Febuxostat + Inosine) in Mitochondrial DiseasesDrug Details:A fixed dose combination of febuxostat and inosine is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Golimumab Biosimilar in Rheumatoid Arthritis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Golimumab Biosimilar in Rheumatoid ArthritisDrug Details:Monoclonal antibody is under development for the treatment of inflammation, rheumatoid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Autoimmune Disorders
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Denosumab Biosimilar in Autoimmune Disorders Drug Details: AVT-03 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Aflibercept Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aflibercept Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration Drug Details: Aflibercept biosimilar (AVT06)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SFA-002 ER in Plaque Psoriasis (Psoriasis Vulgaris)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SFA-002 ER in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details: SFA-002 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy For Hematological Malignancy And Solid Tumor in Bladder Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cellular Immunotherapy For Hematological Malignancy And Solid Tumor in Bladder Cancer Drug Details: Cellular therapy...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nemonoxacin in Diabetic Foot Infection (DFI)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nemonoxacin in Diabetic Foot Infection (DFI) Drug Details: Nemonoxacin (Taigexyn, Wingard) is a non-fluorinated quinolone...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pegenzileukin in Colon Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pegenzileukin in Colon Cancer Drug Details: SAR-444245 (THOR-707) is under development for the treatment of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.